Rankings
▼
Calendar
RIGL FY 2025 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
RIGL
Rigel Pharmaceuticals, Inc.
$541M
FY 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$294M
+64.1% YoY
Gross Profit
$275M
93.3% margin
Operating Income
$125M
42.6% margin
Net Income
$367M
124.7% margin
EPS (Diluted)
$19.48
Cash Flow
Operating Cash Flow
$76M
Free Cash Flow
$76M
Stock-Based Comp.
$13M
Balance Sheet
Total Assets
$514M
Total Liabilities
$122M
Stockholders' Equity
$391M
Cash & Equivalents
$41M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$294M
$179M
+64.1%
Gross Profit
$275M
$161M
+71.0%
Operating Income
$125M
$24M
+418.6%
Net Income
$367M
$17M
+1999.1%
← Q4 2024
All Quarters
Q1 2025 →